{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:25:10Z","timestamp":1781299510837,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00280-012-1924-9","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T02:08:11Z","timestamp":1342663691000},"page":"407-414","source":"Crossref","is-referenced-by-count":24,"title":["Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"70","author":[{"given":"Haruyasu","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Takubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwyn","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,19]]},"reference":[{"key":"1924_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411:355\u2013365","journal-title":"Nature"},{"key":"1924_CR2","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1210\/jc.85.10.3653","volume":"85","author":"N Mauras","year":"2000","unstructured":"Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653\u20133660","journal-title":"J Clin Endocrinol Metab"},{"key":"1924_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-06-0080","volume":"6","author":"D Sachdev","year":"2007","unstructured":"Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1\u201312","journal-title":"Mol Cancer Ther"},{"key":"1924_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1992.65","volume":"65","author":"VM Macaulay","year":"1992","unstructured":"Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311\u2013320","journal-title":"Br J Cancer"},{"key":"1924_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0065-230X(08)60354-1","volume":"68","author":"H Werner","year":"1996","unstructured":"Werner H, Le Roith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183\u2013223","journal-title":"Adv Cancer Res"},{"key":"1924_CR6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/PL00000735","volume":"57","author":"H Werner","year":"2000","unstructured":"Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Molec Life Sci 57:932\u2013942","journal-title":"Cell Molec Life Sci"},{"key":"1924_CR7","first-page":"F105","volume":"1332","author":"R Baserga","year":"1997","unstructured":"Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105\u2013F126","journal-title":"Biochim Biophys Acta"},{"key":"1924_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","volume":"13","author":"SJ Weroha","year":"2008","unstructured":"Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials\u2014early lessons. J Mam Gland Biol Neopl 13:471\u2013483","journal-title":"J Mam Gland Biol Neopl"},{"key":"1924_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.2007-0199","volume":"13","author":"PD Ryan","year":"2008","unstructured":"Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13:16\u201324","journal-title":"Oncologist"},{"key":"1924_CR10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-08-1171","volume":"8","author":"PJ Beltran","year":"2009","unstructured":"Beltran PJ, Mitchell P, Chung Y-A et al (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8:1095\u20131105","journal-title":"Mol Cancer Ther"},{"key":"1924_CR11","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","volume":"27","author":"AW Tolcher","year":"2009","unstructured":"Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800\u20135807","journal-title":"J Clin Oncol"},{"key":"1924_CR12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1677\/JOE-08-0028","volume":"199","author":"E Himpe","year":"2008","unstructured":"Himpe E, Degaillier C, Coppens A, Kooijman R (2008) Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. J Endocrinol 199:69\u201380","journal-title":"J Endocrinol"},{"key":"1924_CR13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1023\/A:1006154108619","volume":"17","author":"M Pollak","year":"1999","unstructured":"Pollak M, Beamer W, Zhang J-C (1999) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383\u2013390","journal-title":"Cancer Metastasis Rev"},{"key":"1924_CR14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/er.20.6.761","volume":"20","author":"V Hwa","year":"1999","unstructured":"Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761\u2013787","journal-title":"Endocr Rev"},{"key":"1924_CR15","first-page":"3796","volume":"8","author":"YS Chang","year":"2002","unstructured":"Chang YS, Gong K, Sun S et al (2002) Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796\u20133802","journal-title":"Clin Cancer Res"},{"key":"1924_CR16","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/sj.onc.1207882","volume":"23","author":"YS Chang","year":"2004","unstructured":"Chang YS, Wang L, Suh Y-A et al (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23:6569\u20136580","journal-title":"Oncogene"},{"issue":"suppl","key":"1924_CR17","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1200\/jco.2011.29.15_suppl.4041","volume":"29","author":"I McCaffery","year":"2011","unstructured":"McCaffery I, Tudor Y, Deng H et al (2011) Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). J Clin Oncol 29(suppl):4041","journal-title":"J Clin Oncol"},{"key":"1924_CR18","doi-asserted-by":"crossref","unstructured":"Ikeda M, Okusaka T, Fukutomi A et al (2011) A phase 1b, open-label study to evaluate the safety of ganitumab (AMG 479) in combination with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Presented at the 2011 European Multidisciplinary Cancer Congress, September 23\u201327, Stockholm (Abstr 6587)","DOI":"10.1016\/S0959-8049(11)71898-6"},{"issue":"suppl","key":"1924_CR19","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/jco.2010.28.15_suppl.4035","volume":"28","author":"HL Kindler","year":"2010","unstructured":"Kindler HL, Richards DA, Stephenson J et al (2010) A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 28(suppl):4035","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00280-012-1924-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T06:35:54Z","timestamp":1561962954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1924-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,19]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1924-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,19]]}}}